Navigation Links
BioLife Solutions Congratulates DCPrime on Its Approved Orphan Medicinal Product Application for DCOne™ Leukemia Vaccine
Date:2/6/2012

BOTHELL, Wash., Feb. 6, 2012 /PRNewswire/ --
BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today recognized its customer DCPrime, a Dutch clinical stage company, on receiving orphan drug designation by the Committee for Orphan Medical Products (COMP) of the European Medicines Agency of DCPrime's novel DCOne platform vaccine indicated for Acute Myeloid Leukemia (AML).

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

"This orphan drug designation is a major step in DCPrime's work towards approval of our AML vaccine, and clearly reflects the COMP's view of the potential of this vaccine in improving survival of patients with AML," said DCPrime Chief Executive Officer and Chief Scientific Officer Dr. Ada Kruisbeek.  

Mike Rice, BioLife Chief Executive Officer, commented on DCPrime's selection of CryoStor by stating, "We congratulate Dr. Kruisbeek and her team on achieving this milestone.  We're pleased to see continued adoption of our novel biopreservation media products in cellular therapy and regenerative medicine applications. The biopreservation efficacy and quality and safety profile of our products are driving increased demand as the regulatory environment for reagents used in the manufacturing, transportation and clinical administration of cell-based products continues to evolve and become more strenuous for our customers."

Kruisbeek continued, "Finding a clinical grade freeze media for DCPrime's final vaccine dose was a high priority. We considered the cost and quality aspects of formulating a freeze media in-house against selecting a pre-formulated GMP manufactured commercial product, and completed a series of comparative experiments.  CryoStor clearly outperformed all other formulations in biopreservation efficacy, and its serum-free, protein-free formulation supported our quality requirements."

About DCPrimeDCPrime is a Dutch clinical stage company, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne™. With this platform, the company can generate off‐the‐shelf DC‐based vaccines for a broad range of cancer types. DCOne‐based DC vaccines share all immune‐stimulatory properties with patient derived DC‐based vaccines, and have the simple logistics of off‐the‐shelf products. A commercial scale manufacturing process to produce DCOne‐based vaccines has been developed, and DCPrime's lead product DCP‐001 is in the clinic in a Phase I/IIa study in patients with Acute Myeloid Leukemia (AML). Several products for solid cancers are in preclinical development, using peptide loaded DCOne‐based vaccines. With this powerful platform, DCPrime has the opportunity to become the gold standard for off‐the‐shelf dendritic cell products.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com  


'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
2. BioLife Solutions Announces Record Quarterly Revenue
3. BioLife Solutions Announces Expanded Customer Base in the High Growth Regenerative Medicine Market
4. Independent Data Published on BioLife Solutions HypoThermosol® and CryoStor®
5. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
6. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
7. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
8. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
9. Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu
10. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
11. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, today reported its fourth quarter and full ... in vivo therapeutic genome editing," said Edward ... zinc finger nuclease (ZFN) technology leads the therapeutic ... core competencies necessary to move our ground-breaking genome ...
(Date:2/9/2016)... HAMILTON, Bermuda, Feb. 9, 2016  Axovant Sciences ... focused on the treatment of dementia, today announced ... address cognitive, behavioral and functional aspects of Lewy ... people in the U.S. Two out of the ... is expected to start later this quarter. In ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: ... global diagnostic ultrasound devices market was valued at US$ 5,381.1 million ... 2019 at a CAGR of 6.8% from 2015 to 2019. ... analyzed for six geographies of North America , ... Latin America , Middle-East and ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has raised ... of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of Iowa, ...
(Date:2/9/2016)... San Diego, California (PRWEB) , ... February 09, ... ... the launch of their new nationwide service to expand access to affordable ... over 30 million hard of hearing individuals in the United States. , “For ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and ... data vendors in the latest KLAS report, Population Health Management 2015: How Far Can ... market for population health management (PHM). The latest KLAS Report, leveraging over 200 ...
Breaking Medicine News(10 mins):